Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial

Iacopo Olivotto(Azienda Ospedaliero-Universitaria Careggi), Amos Katz(NeuroRx Research (Canada)), Theodore P. Abraham(Bristol-Myers Squibb (United States)), Michael R. Preusch, David Zemánek, Roberto Barriales‐Villa, Norbert Frey(Heidelberg University), Artur Oręziak(Institute of Cardiology), Veselin Mitrović, Juan R. Gimeno(Universidad de Murcia), Jonathan Myers(Palo Alto University), Jens Jakob Thune(Amager Hospital), Michael Arad(Tel Aviv University), Jay M. Edelberg, Emeline M. Van Craenenbroeck(Antwerp University Hospital), Wojciech Wojakowski(Cedars-Sinai Medical Center), Sara Saberi(Michigan Medicine), Wanying Li(Guangxi University), Jean‐Noël Trochu, Amy J. Sehnert(Bristol-Myers Squibb (United States)), Jozef Bartúnek(University of Oxford), Anjali Owens(University of Pennsylvania), Cynthia Burstein Waldman(New York Heart Research Foundation), Tim Seidler(Temple College), Antoine Bondue, Jens Mogensen(Odense University Hospital), Miloš Kubánek(Institute of Clinical and Experimental Medicine), Neal K. Lakdawala(Brigham and Women's Hospital), Matthew T. Wheeler(Stanford University), Scott D. Solomon(Brigham and Women's Hospital), Albert Hagège, Pablo García‐Pavía(Universidad Francisco de Vitoria), Ahmad Masri(Oregon Health & Science University), Jeanette Schulz‐Menger(Max Delbrück Center), Olivier Lairez(Hôpital Rangueil), Sheila M. Hegde(Brigham and Women's Hospital), Majdi Halabi, Mondira Bhattacharya(University of Reading), David Zhang(Medical College of Wisconsin), Philippe Charron(Unité de recherche sur les maladies cardiovasculaires et métaboliques), Steven J. Lester(WinnMed), Christoph Axthelm, Carolyn Y. Ho(Brigham and Women's Hospital), H DUENGEN, Morten K. Jensen(Aarhus University Hospital)
The Lancet
August 29, 2020
Cited by 1,198


Related Papers